Improving adherence by investigating the stability of dabigatran outside of the manufacturer’s original packaging: a New Zealand perspective
DE capsules repackaged in DAA demonstrated stability for up to 8 weeks in all NZ storage conditions, confirming the safety of repackaging DE into a DAA.
Authors
- Manisha Sharma (ORCID: https://orcid.org/0000-0002-0692-3223)
- Shih‐Ming Jung (ORCID: https://orcid.org/0000-0001-9716-6098)
- Zainab S Noori
- Dale Griffiths
- Melody Yee‐Man Wong (ORCID: https://orcid.org/0009-0001-0966-4036)
- Jagdish K. Jaiswal
- H. Nakano
- Catherine Huang
Institutions
- University of Auckland (NZ)
- Cancer Society of New Zealand (NZ)
- Maurice Wilkins Centre (NZ)
- Pharmac (NZ)
- nView Medical (United States) (US)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/17425247.2024.2444359
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Auckland